INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 138 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $3,700,013 | -9.6% | 134,497 | +0.2% | 0.00% | 0.0% |
Q4 2023 | $4,091,147 | +6.3% | 134,180 | +10.3% | 0.00% | 0.0% |
Q3 2023 | $3,847,742 | -24.5% | 121,687 | -2.6% | 0.00% | -20.0% |
Q2 2023 | $5,093,748 | +33.1% | 124,908 | +21.6% | 0.01% | +25.0% |
Q1 2023 | $3,828,374 | +18.6% | 102,720 | +11.0% | 0.00% | +33.3% |
Q4 2022 | $3,229,313 | -30.5% | 92,557 | +11.5% | 0.00% | -40.0% |
Q3 2022 | $4,644,000 | +7.0% | 83,008 | -1.1% | 0.01% | 0.0% |
Q2 2022 | $4,342,000 | -40.1% | 83,896 | -15.9% | 0.01% | -16.7% |
Q1 2022 | $7,251,000 | -13.7% | 99,779 | +40.4% | 0.01% | +50.0% |
Q4 2021 | $8,405,000 | -21.4% | 71,077 | -10.8% | 0.00% | -33.3% |
Q3 2021 | $10,692,000 | -35.4% | 79,696 | -22.1% | 0.01% | -25.0% |
Q2 2021 | $16,560,000 | +155.9% | 102,277 | +26.8% | 0.01% | +166.7% |
Q1 2021 | $6,471,000 | +16.3% | 80,637 | -21.2% | 0.00% | 0.0% |
Q4 2020 | $5,563,000 | +117.9% | 102,286 | -20.3% | 0.00% | +50.0% |
Q3 2020 | $2,553,000 | +12.9% | 128,373 | +19.3% | 0.00% | 0.0% |
Q2 2020 | $2,262,000 | +206.1% | 107,636 | +78.0% | 0.00% | +100.0% |
Q1 2020 | $739,000 | +24.2% | 60,455 | +48.8% | 0.00% | – |
Q4 2019 | $595,000 | +77.6% | 40,630 | +61.5% | 0.00% | – |
Q3 2019 | $335,000 | -21.7% | 25,151 | -4.1% | 0.00% | – |
Q2 2019 | $428,000 | +25.5% | 26,214 | +31.1% | 0.00% | – |
Q1 2019 | $341,000 | -6.1% | 19,999 | -24.9% | 0.00% | – |
Q4 2018 | $363,000 | -49.7% | 26,638 | +5.8% | 0.00% | -100.0% |
Q3 2018 | $721,000 | -25.4% | 25,166 | -28.8% | 0.00% | 0.0% |
Q2 2018 | $967,000 | +51.6% | 35,331 | +16.7% | 0.00% | 0.0% |
Q1 2018 | $638,000 | +28.1% | 30,266 | +17.0% | 0.00% | – |
Q4 2017 | $498,000 | -14.9% | 25,876 | +9.9% | 0.00% | -100.0% |
Q3 2017 | $585,000 | +261.1% | 23,538 | +90.1% | 0.00% | – |
Q4 2016 | $162,000 | -33.9% | 12,379 | -14.3% | 0.00% | – |
Q3 2016 | $245,000 | – | 14,440 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |